Predictive peptide receptor radiotherapy using gene expression assays

By detecting the expression level and histological level of specific biomarkers, predicting NET's response to peptide receptor radiation therapy, solving the problem of uncertainty in response prediction in the prior art, and achieving high accuracy personalized treatment recommendations.

CN118910259APending Publication Date: 2024-11-08LIQUID BIOPSY RES LLC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411020843.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2017-11-30
Filing Date
2018-11-29
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

There is uncertainty in the prediction of existing peptide receptor radiation therapy (PRRT) responses to neuroendocrine tumors (NET). Traditional methods such as immunohistochemistry and imaging techniques predict low activity and cannot accurately evaluate radiation susceptibility and therapeutic efficacy.

Method used

By detecting the expression levels of genes such as ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, standardizing and calculating the sum expression levels and histological grades, using specific formulas to predict NET Response to PRRT.

Benefits of technology

Improve the prediction accuracy of whether NET responds to PRRT, with sensitivity and specificity of more than 90%, helping to develop personalized treatment plans.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910259A_ABST
    Figure CN118910259A_ABST
Patent Text Reader

Abstract

The invention relates to predictive peptide receptor radiotherapy using gene expression assays. The present invention relates to a method for providing peptide receptor radiotherapy treatment suggestions for a subject suffering from a neuroendocrine tumor by determining the expression level of each of at least 9 biomarkers comprising ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3 and ALG9. In some embodiments, the method may further comprise determining the expression level of each of NAP1L1, NOL3, and TECPR2.
Need to check novelty before this filing date? Find Prior Art

Description

This application is a divisional application. The application date of the original application is November 29, 2018, the application number is 201880077556.7 (PCT / US2018 / 062964), and the name of the invention is "Predicting peptide receptor radiotherapy using gene expression assays."

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to and the benefit of U.S. Provisional Application No. 62 / 592,647, filed on November 30, 2017, the contents of which are incorporated herein by reference in their entirety.

[0002] Sequence Listing This application contains a sequence listing, which is submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. The ASCII copy was created on November 15, 2018, is named "LBIO-003_001WO_ST25.txt", and is 52,601 bytes in size. Field of the Invention

[0003] The present invention relates to the use of gene expression assays to predict response to peptide receptor radiation therapy (PRRT). Background of the Invention In neuroendocrine tumors, the most commonly used form of radionuclide therapy is peptide receptor radionuclide therapy (PRRT). This exploits the overexpression of the somatostatin receptor, a central feature of NETs. PRRT uses the somatostatin analog octreotide as a peptide that targets the receptor. Radiolabeled derivatives of this analog include 177 Lu-DOTA-Tyr 3 ,Thr 8 -Octreotide or 177 Lu-octreotate. This treatment strategy is widely used in Europe and has recently been introduced in the United States.

[0005] Multiple uncontrolled studies in pancreatic and bronchopulmonary NETs have shown 177 Lu-octreotate is effective, with objective responses and a positive impact on survival parameters. Recently, a phase III randomized controlled trial of midgut NETs based on standard octreotide LAR therapy (NETTER-1) showed that 177 Lu-octreotate is more effective than high-dose octreotide somatostatin analogs.

[0006] Currently, the decision to use PRRT is based on the expression level of somatostatin receptor (SSR). This is usually determined by tissue biopsy and immunohistochemistry or by somatostatin-based scans (eg, 111 In-pentetrexate scan or 68Ga-DOTATATE / DOTATOCPET / CT) to obtain information.

[0007] However, immunohistochemistry is limited because somatostatin receptor expression in tumors is heterogeneous, individual antibodies may have different binding affinities, and evaluation of the staining by a pathologist does not provide an objective output. Other limitations include the inability to define receptor function and the inability to determine expression in other tumors that have not been biopsied.

[0008] Evaluation of somatostatin expression using imaging involves comparing the uptake of radioactivity in the target lesion with that in non-tumor organs such as the spleen. The extent of uptake is graded from low to strongly positive according to the Krenning scale. However, this approach has low predictive activity. For example, a strongly positive tumor (Krenning grade 4, in 111 In-pentetreotide scanning) has only a 60% response accuracy. Various semi-quantitative tools have been tried, but all have failed. Expression of somatostatin receptors can be used to identify tumors that are targetable and amenable to isotope delivery, but does not provide an accurate assessment of the likelihood of radiosusceptibility (and therapeutic efficacy).

[0009] Other clinical parameters (such as disease extent), tumor grade, and biomarkers (such as chromogranin A) have been investigated as potential predictive tools. However, although grading using morphological criteria or KI67 assessment has shown some clinical utility, none has been shown to be a robust predictor of effective treatment response. The accuracy of grading is approximately 70% for predicting PRRT. In general, low-grade tumors (well-differentiated grade 1 or 2, i.e., KI67 is detectable in ≤20% of tumor cells) respond to PRRT more often than high-grade (KI67>20%) tumors. However, grading is limited by tumor heterogeneity, observer subjectivity, and low κ values. In addition, tissue biopsies are rarely obtained from more than one location, and metastases are often significantly different from the primary lesion biopsied for diagnosis.

[0010] Clearly, the complexity of molecular drivers in tumor cells that define responsiveness to treatment in cancer or disease progression requires more sophisticated evaluation tools. Technological developments based on the delineation of the molecular biology of a variety of cancers have led to the evolution of strategies to evaluate circulating molecular information generated from neoplasia. This strategy, or "liquid biopsy," has proven very effective in lung neoplasia, for example for monitoring therapeutic response to EFGR inhibitors by identifying mutation T790M in circulating tumor DNA. The opportunity to limit biopsies, define potential therapeutic targets, and provide real-time monitoring tools to assess disease evolution has considerable clinical appeal. SUMMARY OF THE INVENTION The present disclosure provides a method for providing a peptide receptor radiation therapy (PRRT) treatment recommendation for a subject with a neuroendocrine tumor (NET), the method comprising: determining the expression levels of at least 9 biomarkers from the test sample by contacting the test sample from the subject with a plurality of reagents that specifically detect the expression of at least 9 biomarkers, wherein the 9 biomarkers include ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, and ALG9; and normalizing the expression level of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, and PLD3 to the expression level of ALG9, thereby obtaining an expression level of ARAF1; 1. a standardized expression level of each of BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, and PLD3; summing the standardized expression levels of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, and PLD3 to obtain a total expression level; determining a first score, wherein the first score is 1 when the total expression level is equal to or greater than a first predetermined cutoff value, or the first score is 0 when the total expression level is lower than the first predetermined cutoff value; determining a second score based on the histological grade of the NET, wherein the second score is 1 when the NET is designated as a high grade, or the second score is 0 when the NET is designated as a low grade; calculating a third score based on the following formula: The third score = 39.22787 - 40.80341 * (first score) - 18.441 * (second score); and when the third score is equal to or less than the second predetermined cutoff value, providing a suggestion that the NET will respond to PRRT, or when the third score is higher than the second predetermined cutoff value, providing a suggestion that the NET will not respond to PRRT.

[0012] In the aforementioned method of the present disclosure, the first predetermined cutoff value may be 5.9. The second predetermined cutoff value may be 0.

[0013] The present disclosure provides a method for providing a peptide receptor radiation therapy (PRRT) treatment recommendation for a subject with a neuroendocrine tumor (NET), the method comprising: determining the expression levels of at least 12 biomarkers from the test sample by contacting the test sample from the subject with a plurality of reagents that specifically detect the expression of at least 12 biomarkers, wherein the 12 biomarkers include ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3, TECPR2, and ALG9; and normalizing the expression level of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3, and TECPR2 to the expression level of ALG9, thereby obtaining an expression level of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3, and TECPR2. A method for determining a standardized expression level of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3, and TECPR2 is described herein; wherein the standardized expression level of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3, and TECPR2 is summed to obtain a total expression level; a first score is determined, wherein the first score is 1 when the total expression level is equal to or greater than a first predetermined cutoff value, or the first score is 0 when the total expression level is less than the first predetermined cutoff value; a second score is determined based on the histological grade of the NET, wherein the second score is 1 when the NET is designated as a high grade, or the second score is 0 when the NET is designated as a low grade; and a third score is calculated based on the following formula: The third score = 39.22787 - 40.80341 * (first score) - 18.441 * (second score); and when the third score is equal to or less than the second predetermined cutoff value, providing a suggestion that the NET will respond to PRRT, or when the third score is higher than the second predetermined cutoff value, providing a suggestion that the NET will not respond to PRRT.

[0014] In the aforementioned method of the present disclosure, the first predetermined cutoff value may be 10.9. The second predetermined cutoff value may be 0.

[0015] The present disclosure provides a method for providing a peptide receptor radiation therapy (PRRT) treatment recommendation for a subject with a neuroendocrine tumor (NET), the method comprising: determining the expression level of each of at least 12 biomarkers from the test sample by contacting the test sample from the subject with a plurality of reagents that specifically detect the expression of at least 12 biomarkers, wherein the 12 biomarkers include ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3, TECPR2, and ALG9; The expression level of each of CPR2 is normalized to the expression level of ALG9 to obtain a normalized expression level of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3, and TECPR2; the normalized expression levels of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3, and TECPR2 are summed to obtain a total expression level; and when the total expression level is equal to or greater than a predetermined cutoff value, a suggestion is provided that the NET will respond to PRRT, or when the total expression level is less than the predetermined cutoff value, a suggestion is provided that the NET will not respond to PRRT.

[0016] In the aforementioned method of the present disclosure, the predetermined cutoff value may be 10.9.

[0017] The present disclosure provides a method for providing a peptide receptor radiation therapy (PRRT) treatment recommendation for a subject with a low-grade or high-grade neuroendocrine tumor (NET), the method comprising: determining the expression level of each of at least 12 biomarkers from the test sample by contacting the test sample from the subject with a plurality of reagents that specifically detect the expression of at least 12 biomarkers, wherein the 12 biomarkers include ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3, TECPR2, and ALG9; The expression level of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3 and TECPR2 is normalized to the expression level of ALG9 to obtain a normalized expression level of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3 and TECPR2; the normalized expression level of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3 and TECPR2 is summed to obtain a total expression level; and when the total expression level is equal to or greater than a predetermined cutoff value, a suggestion is provided that the low-grade or high-grade NET will respond to PRRT, or when the total expression level is less than the predetermined cutoff value, a suggestion is provided that the low-grade or high-grade NET will not respond to PRRT.

[0018] In the aforementioned method of the present disclosure, the predetermined cutoff value may be 10.9.

[0019] The present disclosure provides a method for providing a peptide receptor radiation therapy (PRRT) treatment recommendation for a subject with a low-grade or high-grade neuroendocrine tumor (NET), the method comprising: determining the expression level of each of at least 9 biomarkers from the test sample by contacting the test sample from the subject with a plurality of reagents that specifically detect the expression of at least 9 biomarkers, wherein the 9 biomarkers include ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, and ALG9; and comparing the expression level of each of the at least 9 biomarkers from the test sample to the expression level of each of the at least 9 biomarkers from the test sample. The expression level of each is normalized to the expression level of ALG9 to obtain a normalized expression level of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, and PLD3; the normalized expression levels of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, and PLD3 are summed to obtain a total expression level; and when the total expression level is equal to or greater than a predetermined cutoff value, a recommendation is provided that the low-grade or high-grade NET will respond to PRRT, or when the total expression level is less than the predetermined cutoff value, a recommendation is provided that the low-grade or high-grade NET will not respond to PRRT.

[0020] In the methods of the present disclosure, at least one of the at least 9 biomarkers may be RNA, cDNA or protein. In aspects where the biomarker is RNA, the RNA may be reverse transcribed to produce cDNA, and the expression level of the produced cDNA may be detected. In aspects where the biomarker is a protein, the protein may be detected by forming a complex between the biomarker and a labeled probe or primer.

[0021] In the methods of the present disclosure, the expression level of a biomarker can be detected by forming a complex between the biomarker and a labeled probe or primer.

[0022] In the method of the present disclosure, when the biomarker is RNA or cDNA, the RNA or cDNA can be detected by forming a complex between the RNA or cDNA and a labeled nucleic acid probe or primer. The complex between the RNA or cDNA and the labeled nucleic acid probe or primer can be a hybridization complex.

[0023] In the methods of the present disclosure, the test sample may be blood, serum, plasma or neoplastic tissue. In the methods of the present disclosure, the test sample may be blood.

[0024] In the methods of the present disclosure, when the NETs are poorly differentiated, the NETs can be designated as high grade.

[0025] In the methods of the present disclosure, the NET can be designated as low grade when the NET is a well-differentiated, bronchial typical carcinoid or bronchial atypical carcinoid.

[0026] The methods of the present disclosure may further include administering PRRT to the subject when the third score is equal to or less than a second predetermined cutoff value.

[0027] The methods of the present disclosure may further comprise administering PRRT to the subject when the total expression level is equal to or greater than a predetermined cutoff value.

[0028] The methods of the present disclosure may have a sensitivity greater than 90%. The methods of the present disclosure may have a specificity greater than 90%.

[0029] The present disclosure provides a method for treating a subject with peptide receptor radiation therapy (PRRT), wherein the subject suffers from a neuroendocrine tumor (NET), the method comprising: determining the expression levels of at least 9 biomarkers from the test sample by contacting the test sample from the subject with a plurality of reagents that specifically detect the expression of at least 9 biomarkers, wherein the 9 biomarkers include ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, and ALG9; and normalizing the expression level of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, and PLD3 to the expression level of ALG9, thereby obtaining an expression level of ARAF1; 1. a standardized expression level of each of BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, and PLD3; summing the standardized expression levels of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, and PLD3 to obtain a total expression level; determining a first score, wherein the first score is 1 when the total expression level is equal to or greater than a first predetermined cutoff value, or the first score is 0 when the total expression level is lower than the first predetermined cutoff value; determining a second score based on the histological grade of the NET, wherein the second score is 1 when the NET is designated as a high grade, or the second score is 0 when the NET is designated as a low grade; calculating a third score based on the following formula: The third score=39.22787-40.80341*(first score)-18.441*(second score); and when the third score is equal to or greater than a predetermined cutoff value, administering PRRT to the subject.

[0030] The present disclosure provides a method of treating a subject with peptide receptor radiation therapy (PRRT), wherein the subject has a neuroendocrine tumor (NET), the method comprising: determining the expression levels of at least 12 biomarkers from the test sample by contacting the test sample from the subject with a plurality of reagents that specifically detect the expression of at least 12 biomarkers, wherein the 12 biomarkers include ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3, TECPR2, and ALG9; and normalizing the expression level of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3, and TECPR2 to the expression level of ALG9, thereby obtaining an ARAF1 expression level. A standardized expression level of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3 and TECPR2; summing the standardized expression levels of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3 and TECPR2 to obtain a total expression level; determining a first score, wherein the first score is 1 when the total expression level is equal to or greater than a first predetermined cutoff value, or the first score is 0 when the total expression level is lower than the first predetermined cutoff value; determining a second score based on the histological grade of the NET, wherein the second score is 1 when the NET is designated as high grade, or the second score is 0 when the NET is designated as low grade; and calculating a third score based on the following formula: The third score=39.22787-40.80341*(first score)-18.441*(second score); and when the third score is equal to or greater than a predetermined cutoff value, administering PRRT to the subject.

[0031] The present disclosure provides a method of treating a subject with peptide receptor radiation therapy (PRRT), wherein the subject has a neuroendocrine tumor (NET), the method comprising: determining the expression level of each of at least 12 biomarkers from the test sample by contacting the test sample from the subject with a plurality of reagents that specifically detect the expression of at least 12 biomarkers, wherein the 12 biomarkers include ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3, TECPR2, and ALG9; The expression level of each of NK2, PLD3, NAP1L1, NOL3 and TECPR2 is normalized to the expression level of ALG9 to obtain the normalized expression level of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3 and TECPR2; the normalized expression levels of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3 and TECPR2 are summed to obtain the total expression level; and when the total expression level is equal to or greater than a predetermined cutoff value, PRRT is administered to the subject.

[0032] The present disclosure provides a method of treating a subject with peptide receptor radiation therapy (PRRT), wherein the subject has a low-grade or high-grade neuroendocrine tumor (NET), the method comprising: determining the expression level of each of at least 12 biomarkers from the test sample by contacting the test sample from the subject with a plurality of reagents that specifically detect the expression of at least 12 biomarkers, wherein the 12 biomarkers include ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3, TECPR2, and ALG9; 2. The expression level of each of PANK2, PLD3, NAP1L1, NOL3 and TECPR2 is normalized to the expression level of ALG9 to obtain the standardized expression level of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3 and TECPR2; the standardized expression levels of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3 and TECPR2 are summed to obtain the total expression level; and when the total expression level is equal to or greater than a predetermined cutoff value, PRRT is given to the subject.

[0033] The present disclosure provides a method for treating a subject with peptide receptor radiation therapy (PRRT), wherein the subject suffers from a low-grade or high-grade neuroendocrine tumor (NET), the method comprising: determining the expression level of each of at least 9 biomarkers from the test sample by contacting the test sample from the subject with a plurality of reagents that specifically detect the expression of at least 9 biomarkers, wherein the 9 biomarkers include ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, and ALG9; The expression level of each of RAF-1, ATP6V1H, OAZ2, PANK2 and PLD3 is normalized to the expression level of ALG9 to obtain the standardized expression level of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2 and PLD3; the standardized expression level of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2 and PLD3 is summed to obtain the total expression level; and when the total expression level is equal to or greater than a predetermined cutoff value, PRRT is administered to the subject.

[0034] In the methods of the present disclosure, administering PRRT to a subject may include administering a PRRT based on 177 Lu's PRRT. Based on 177 Lu's PRRT can be 177 Lu-DOTA-Tyr 3 -Thr 8 -Octreotide.

[0035] In the methods of the present disclosure, about 7.4 GBq (200 mCi) may be administered about once every 8 weeks. 177 Lu-DOTA-Tyr 3 -Thr 8 - Octreotide, for a total of about 4 doses. Can be given about once every 8 weeks at a dose of about 6.5 GBq 177 Lu-DOTA-Tyr 3 -Thr 8 - Octreotide, for a total of about 4 doses. Can be given about once every 8 weeks at a dose of about 4.6 GBq 177 Lu-DOTA-Tyr 3 -Thr 8 -Octreotide, continued for a total of about 4 doses.

[0036] Can be given about once every 8 weeks at a dose of about 3.2 GBq (100 mCi) 177 Lu-DOTA-Tyr 3 -Thr 8 - Octreotide, for a total of about 4 doses. Can be given about once every 8 weeks at a dose of about 3.7 GBq 177 Lu-DOTA-Tyr 3 -Thr 8 -Octreotide, continued for a total of about 4 doses.

[0037] In the method disclosed herein, based on 177 Lu's PRRT can be given intravenously. 177 Lu's PRRT can be given intra-arterially.

[0038] In some embodiments of any one of the above aspects, the method further comprises administering PRRT to the subject when it is predicted that the NET will respond to PRRT.

[0039] Any of the above aspects may be combined with any other aspect.

[0040] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art to which the present disclosure belongs. In the specification, the singular also includes the plural, unless the context clearly dictates otherwise; as an example, the terms "a", "an" and "the" are to be understood as singular or plural, and the term "or" is to be understood as inclusive. For example, "an element" means one or more elements. Throughout the specification, the word "comprising" or variations such as "comprises" or "comprising" are to be understood to mean including the elements, integers or steps, or groups of elements, integers or steps, but not excluding any other elements, integers or steps, or groups of elements, integers or steps. Approximately can be understood as within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05% or 0.01% of the stated value. Unless the context clearly dictates otherwise, all numerical values ​​provided herein are modified by the term "about."

[0041] Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below. All disclosures, patent applications, patents and other references mentioned herein are combined by reference in their entirety. The references cited herein are not admitted to be the prior art of the claimed invention. In the event of a conflict, this specification (including definitions) shall prevail. In addition, materials, methods and examples are illustrative only and are not intended to be restrictive. Other features and advantages of the present disclosure will be apparent from the following detailed description and claims. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 Figure 2 is a graph showing the utility of the PRRT prediction quotient for predicting PFS in the test cohort. Test cohort (n=72): mPFS was not derived in patients predicted to respond by PPQ before treatment (biomarker positive). For those predicted to not respond (biomarker negative), mPFS was 8 months. This was significantly different (HR 36.4, p<0.0001).

[0043] Figure 2 Figure 2 is a graph showing the utility of the PRRT prediction quotient for predicting PFS in validation cohort I. No mPFS was derived in those predicted to respond. In those predicted to not respond, mPFS was 14 months (HR 17.7, p<0.0001).

[0044] Figure 3Figure 1 shows the utility of the PRRT prediction quotient for predicting PFS in validation cohort II. No mPFS was derived in predicting responders. For those predicted to have no response, mPFS was 9.7 months. This was a significant difference (HR 92, p<0.0001).

[0045] Figure 4 Figure 2 is a graph showing the utility of the PRRT prediction quotient for predicting PFS in SSA-treated patients. In predicted responders, mPFS was 10 months. For those predicted to not respond, mPFS was not derived. This was not significantly different (HR 0.8, p = NS).

[0046] Figure 5 Figure 2 is a graph showing the utility of the PRRT prediction quotient for predicting PFS in patients enrolled in the registry. In predicted responders, the mPFS was 10 months. For those predicted to not respond, the mPFS was 15. This was not significantly different (HR 0.9, p=NS).

[0047] Figures 6A-6D Figures are diagrams illustrating the utility of PPQ as a predictive marker.

[0048] Fig. 6A PPQ for PRRT and comparison cohorts in biomarker-positive cases is shown. In predicted responders (i.e., PPQ "positive" group), no mPFS was derived in patients treated with PRRT (validation cohort I (n=44) and validation cohort II (n=42)) compared with those treated with SSA or in the registry.

[0049] Figure 6B PPQ in PRRT and comparator cohorts among biomarker-negative cases is shown: In predicted non-responders (ie, PPQ “negative” group), mPFS was similar whether treated with PRRT or not.

[0050] Figure 6C Ideal predictive biomarker shown to be "positive": In this idealized example, a "treatment effect", ie, a quantitative difference in mPFS, is noted between those treated (mPFS not determined) and those not treated (17 months).

[0051] Fig.6D Showing an ideal predictive biomarker "negative": In this idealized example, mPFS would be the same (18 months) regardless of treatment.

[0052] Figure 7 Shown is progression-free survival (PFS) of PPQ-negative subjects following treatment with PRRT or a combination of PRRT and chemotherapy. DETAILED DESCRIPTION OF THE INVENTION The details of the present invention are set forth in the following accompanying description. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, illustrative methods and materials are now described. Other features, objects and advantages of the present invention will be apparent from the description and claims. In the specification and the appended claims, the singular also includes the plural, unless the context clearly provides otherwise. Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those of ordinary skill in the art to which the present invention belongs. All patents and disclosures cited in this specification are incorporated herein by reference in their entirety.

[0054] The present invention is based in part on the following discovery: the expression level of circulating neuroendocrine tumor (NET) transcripts can predict whether patients with NET respond to peptide receptor radiation therapy (PRRT). Circulating NET transcripts include the following: (a) growth factor (GF) related genes (ARAF1, BRAF, KRAS and RAF-1); and (b) genes involved in metabolism (M) (ATP6V1H, OAZ2, PANK2 and PLD3). The expression levels of these genes can be normalized to ALG9 (used as a housekeeping gene). It was found that when the total expression level of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3 (after normalization) is equal to or greater than a predetermined cutoff value, regardless of the histological grade of NET, NET will respond to PRRT. In addition, when the total expression level of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3 (after normalization) is less than a predetermined cutoff value, the NET will not respond to PRRT regardless of the histological grade of the NET. In some embodiments, the circulating NET transcripts may further include genes involved in proliferation (P) (NAP1L1, NOL3 and TECPR2). The expression levels of NAP1L1, NOL3 and TECPR2 can also be measured and normalized to the expression level of ALG9.

[0055] In some embodiments, the total expression level of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3 can be obtained by performing the following steps: (a1) determining the expression level of each of the at least 9 biomarkers from the test sample by contacting the test sample from the subject with a plurality of reagents that specifically detect the expression of at least 9 biomarkers, wherein the 9 biomarkers include ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3 and ALG9; (b1) normalizing the expression level of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2 and PLD3 to the expression level of ALG9 to obtain the normalized expression level of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2 and PLD3; and (c1) summing the normalized expression level of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2 and PLD3 to obtain the total expression level.

[0056] Alternatively, the total expression level of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, and PLD3 can also be obtained by performing the following steps after determining the expression level of each of the at least 9 biomarkers: (a2) summing the expression level of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, and PLD3 to obtain a total value; and (b2) normalizing the total value to the expression level of ALG9 to obtain a total expression level.

[0057] One aspect of the present disclosure provides a method for providing a PRRT treatment recommendation for a subject with a low-grade or high-grade NET, the method comprising providing a recommendation that a low-grade or high-grade NET will respond to PRRT when the sum expression level of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3 is equal to or greater than a predetermined cutoff value, or providing a recommendation that a low-grade or high-grade NET will not respond to PRRT when the sum expression level is less than a predetermined cutoff value. In some embodiments, when the NET is poorly differentiated, the NET is designated as high grade. In some embodiments, when the NET is a well-differentiated, bronchial typical carcinoid or bronchial atypical carcinoid, the NET is designated as low grade.

[0058] In a similar aspect, the present disclosure provides a method for providing a PRRT treatment recommendation for a subject having NET, the method comprising providing a recommendation that the NET will respond to PRRT when the sum expression level of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3 is equal to or greater than a predetermined cutoff value, or providing a recommendation that the NET will not respond to PRRT when the sum expression level is less than a predetermined cutoff value.

[0059] In some embodiments, the predetermined cutoff value is 5.9. The cutoff value is derived from the following situation: wherein the total expression level of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3 is 5.9 times the expression level of ALG9.

[0060] On the other hand, the histological grade of NET can also be used together with the expression level of circulating neuroendocrine tumor transcripts. Therefore, the present disclosure provides a method for providing PRRT treatment recommendations for subjects with NET, the method comprising: (a3) ​​determining a first score, wherein when the total expression level of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3 is equal to or greater than a first predetermined cutoff value, the first score is 1, or when the total expression level is lower than the first predetermined cutoff value, the first score is 0; (b3) determining a second score based on the histological grade of NET, wherein when the NET is designated as a high grade, the second score is 1, or when the NET is designated as a low grade, the second score is 0; (c3) calculating a third score based on the following formula: third score = 39.22787 - 40.80341 * (first score) - 18.441 * (second score); and (d3) providing a recommendation that the NET will respond to PRRT when the third score is equal to or less than the second predetermined cutoff value, or providing a recommendation that the NET will not respond to PRRT when the third score is above the second predetermined cutoff value.

[0061] In some embodiments, the first predetermined cutoff value is 5.9. The cutoff value is derived from the following situation: wherein the total expression level of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3 is 5.9 times the expression level of ALG9.

[0062] In some embodiments, the second predetermined cutoff value is zero.

[0063] In one aspect, the present disclosure provides a method for providing a PRRT treatment recommendation for a subject with low-grade or high-grade NET, the method comprising: (a) determining the expression level of each of the at least 12 biomarkers from the test sample by contacting the test sample from the subject with a plurality of reagents that specifically detect the expression of at least 12 biomarkers, wherein the 12 biomarkers include ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3, TECPR2, and ALG9; (b) converting the expression level of each of the at least 12 biomarkers from the test sample to the PRRT treatment recommendation; (c) summing the standardized expression levels of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3, and TECPR2 to obtain a total expression level; and (d) providing a recommendation that a low-grade or high-grade NET will respond to PRRT when the total expression level is equal to or greater than a predetermined cutoff value, or providing a recommendation that a low-grade or high-grade NET will not respond to PRRT when the total expression level is less than a predetermined cutoff value. In some embodiments, the predetermined cutoff value is 10.9.

[0064] In another aspect, the present disclosure provides a method for providing a PRRT treatment recommendation for a subject with NET, the method comprising: (a) determining the expression level of each of the at least 12 biomarkers from the test sample by contacting the test sample from the subject with a plurality of reagents that specifically detect the expression of at least 12 biomarkers, wherein the 12 biomarkers include ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3, TECPR2, and ALG9; (b) converting each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3, and TECPR2 to a PRRT treatment recommendation; (c) summing the normalized expression levels of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3, and TECPR2 to obtain a total expression level; and (d) providing a suggestion that the NET will respond to PRRT when the total expression level is equal to or greater than a predetermined cutoff value, or providing a suggestion that the NET will not respond to PRRT when the total expression level is less than a predetermined cutoff value. In some embodiments, the predetermined cutoff value is 10.9.

[0065] In another aspect, the present disclosure provides a method for providing a PRRT treatment recommendation for a subject with NET, the method comprising: (a) determining the expression levels of at least 12 biomarkers from the test sample by contacting the test sample from the subject with a plurality of reagents that specifically detect the expression of at least 12 biomarkers, wherein the 12 biomarkers include ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3, TECPR2, and ALG9; (b) normalizing the expression level of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3, TECPR2, and ALG9 to the expression level of ALG9, thereby obtaining an expression level of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3, and TECPR2; (c) summing the standardized expression levels of each of RAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3 and TECPR2 to obtain a total expression level; (d) determining a first score, wherein the first score is 1 when the total expression level is equal to or greater than a first predetermined cutoff value, or the first score is 0 when the total expression level is lower than the first predetermined cutoff value; (e) determining a second score based on the histological grade of the NET, wherein the second score is 1 when the NET is designated as a high grade, or the second score is 0 when the NET is designated as a low grade; (f) calculating a third score based on the following formula: The third score = 39.22787 - 40.80341 * (first score) - 18.441 * (second score); and (f) when the third score is equal to or less than a second predetermined cutoff value, providing a suggestion that the NET will respond to PRRT, or when the third score is above the second predetermined cutoff value, providing a suggestion that the NET will not respond to PRRT. In some embodiments, the first predetermined cutoff value is 10.9. In some embodiments, the second predetermined cutoff value is 0.

[0066] Responders (ie, NET will respond to PRRT) are individuals predicted by the methods described herein to achieve stable disease or show a partial response. Non-responders (ie, NET will not respond to PRRT) are individuals showing progressive disease.

[0067] The test sample can be any biological fluid obtained from a subject. Preferably, the test sample is blood, serum, plasma, or neoplastic tissue. In some embodiments, the test sample is blood. In some embodiments, the test sample is serum. In some embodiments, the test sample is plasma.

[0068] Expression levels can be measured in a variety of ways, including (but not limited to): measuring the mRNA encoded by the selected gene; measuring the amount of protein encoded by the selected gene; and measuring the activity of the protein encoded by the selected gene.

[0069] Biomarkers can be RNA, cDNA or protein. When the biomarker is RNA, the RNA can be reverse transcribed to produce cDNA (such as by RT-PCR), and the expression level of the produced cDNA can be detected. The expression level of the biomarker can be detected by forming a complex between the biomarker and the labeled probe or primer. When the biomarker is RNA or cDNA, the RNA or cDNA can be detected by forming a complex between the RNA or cDNA and the labeled nucleic acid probe or primer. The complex between RNA or cDNA and the labeled nucleic acid probe or primer can be a hybrid complex.

[0070] Gene expression can also be detected by microarray analysis. Microarray technology can also be used to identify or confirm differential gene expression. Therefore, microarray technology can be used to measure the expression profile biomarkers in fresh or fixed tissues. In this method, the target polynucleotide sequence (including cDNA and oligonucleotide) is plated or arranged on a microchip substrate. The arranged sequence is then hybridized with a specific DNA probe from a target cell or tissue. The source of mRNA is generally the total RNA isolated from a biological sample, and corresponding normal tissues or cell lines can be used to determine differential expression.

[0071] In some embodiments of microarray technology, cDNA clone inserts amplified by PCR are applied to substrates in dense arrays. Preferably, at least 10,000 nucleotide sequences are applied to substrates. Microarrayed genes are fixed on microchips with 10,000 units each, suitable for hybridization under stringent conditions. Fluorescently labeled cDNA probes can be produced by reverse transcription of RNA extracted from target tissues by incorporating fluorescent nucleotides. The labeled cDNA probes applied to the chip specifically hybridize with each DNA spot on the array. After strict washing to remove non-specifically bound probes, the microarray chip is scanned by a device (such as confocal laser microscopy) or by another detection method (such as a CCD camera). The quantification of the hybridization of each array unit allows the evaluation of the corresponding mRNA abundance. Using dual-color fluorescence, the cDNA probes labeled separately produced from two RNA sources are hybridized in pairs with the array. Therefore, the relative abundance of transcripts corresponding to each specified gene from two sources is determined simultaneously. Microarray analysis can be performed by commercially available equipment according to the manufacturer's protocol.

[0072] In some embodiments, qRT-PCR can be used to detect biomarkers in biological samples. The first step of gene expression profiling by RT-PCR is to extract RNA from the biological sample, then reverse transcribe the RNA template into cDNA, and amplify it by PCR reaction. Depending on the target of expression profiling, specific primers, random hexamer or oligo-dT primers are usually used to trigger the reverse transcription reaction step. Two commonly used reverse transcriptases are avian myeloblastosis virus reverse transcriptase (avilomyeloblastosis virus reverse transcriptase) (AMV-RT) and Moloneymurine leukemia virus reverse transcriptase (Moloneymurine leukemia virus reverse transcriptase) (MLV-RT).

[0073] When the biomarker is a protein, the protein can be detected by forming a complex between the protein and a labeled antibody. The label can be any label, such as a fluorescent label, a chemiluminescent label, a radioactive label, etc. Exemplary methods for protein detection include, but are not limited to, enzyme immunoassay (EIA), radioimmunoassay (RIA), Western blot analysis, and enzyme-linked immunosorbent assay (ELISA). For example, biomarkers can be detected by ELISA, in which biomarker antibodies are bound to a solid phase, and enzyme-antibody conjugates are used to detect and / or quantify the biomarkers present in the sample. Alternatively, a western blot assay can be used, in which dissolved and separated biomarkers are bound to nitrocellulose paper. The combination of a highly specific and stable liquid conjugate with a sensitive chromogenic substrate allows for rapid and accurate identification of samples.

[0074] In some embodiments, the methods described herein further include administering PRRT to the subject when it is predicted that NET will respond to PRRT. For example, according to some aspects of the present disclosure, the method further includes administering PRRT to the subject when the total expression level is equal to or greater than a predetermined cutoff value. According to other aspects of the present disclosure, the method further includes administering PRRT to the subject when the third score is equal to or less than a second predetermined cutoff value. In PRRT, a cell-targeting protein (or peptide) called octreotide is combined with a small amount of radioactive material or radionuclide to form a special type of radiopharmaceutical called a radiopeptide. When injected into the patient's bloodstream, this radiopeptide travels to and binds to neuroendocrine tumor cells, delivering high doses of radiation to the cancer.

[0075] When it is predicted that the NET will not respond to PRRT, the methods described herein further comprise monitoring the subject over a period of time (eg, 1-6 months).

[0076] In some embodiments, the methods described herein may have a specificity, sensitivity, and / or accuracy of at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.

[0077] The present disclosure provides a method for treating a subject with peptide receptor radiation therapy (PRRT), wherein the subject has a neuroendocrine tumor (NET), the method comprising: determining the expression levels of at least 9 biomarkers from the test sample by contacting the test sample from the subject with a plurality of reagents that specifically detect the expression of at least 9 biomarkers, wherein the 9 biomarkers include ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, and ALG9; normalizing the expression level of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, and PLD3 to the expression level of ALG9, thereby obtaining an expression level of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, and PLD3; The invention relates to a method for treating a NET according to the present invention. The method comprises the following steps: determining a standardized expression level of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2 and PLD3; summing the standardized expression levels of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2 and PLD3 to obtain a total expression level; determining a first score, wherein the first score is 1 when the total expression level is equal to or greater than a first predetermined cutoff value, or the first score is 0 when the total expression level is lower than the first predetermined cutoff value; determining a second score based on the histological grade of the NET, wherein the second score is 1 when the NET is designated as a high grade, or the second score is 0 when the NET is designated as a low grade; calculating a third score based on the following formula: third score = 39.22787-40.80341*(first score)-18.441*(second score); and administering PRRT to the subject when the third score is equal to or greater than the predetermined cutoff value.

[0078] The present disclosure provides a method of treating a subject with peptide receptor radiation therapy (PRRT), wherein the subject has a neuroendocrine tumor (NET), the method comprising: determining the expression levels of at least 9 biomarkers from the test sample by contacting the test sample from the subject with a plurality of reagents that specifically detect the expression of at least 9 biomarkers, wherein the 9 biomarkers include ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, and ALG9; and normalizing the expression level of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, and PLD3 to the expression level of ALG9, thereby obtaining a normalized expression level of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, and PLD3. level; summing the standardized expression levels of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2 and PLD3 to obtain a total expression level; determining a first score, wherein the first score is 1 when the total expression level is equal to or greater than a first predetermined cutoff value, or the first score is 0 when the total expression level is lower than the first predetermined cutoff value; determining a second score based on the histological grade of the NET, wherein the second score is 1 when the NET is designated as a high grade, or the second score is 0 when the NET is designated as a low grade; calculating a third score based on the following formula: third score=39.22787-40.80341*(first score)-18.441*(second score); and when the third score is equal to or greater than the predetermined cutoff value, administering PRRT to the subject, or when the third score is less than the predetermined cutoff value, administering an alternative treatment modality to the subject.

[0079] The present disclosure provides a method for treating a subject with peptide receptor radiation therapy (PRRT), wherein the subject has a neuroendocrine tumor (NET), the method comprising: determining the expression levels of at least 12 biomarkers from the test sample by contacting the test sample from the subject with a plurality of reagents that specifically detect the expression of at least 12 biomarkers, wherein the 12 biomarkers include ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3, TECPR2, and ALG9; and normalizing the expression level of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3, and TECPR2 to the expression level of ALG9, thereby obtaining an expression level of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3, and TECPR2. 2. a standardized expression level of each of PLD3, NAP1L1, NOL3 and TECPR2; summing the standardized expression levels of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3 and TECPR2 to obtain a total expression level; determining a first score, wherein the first score is 1 when the total expression level is equal to or greater than a first predetermined cutoff value, or the first score is 0 when the total expression level is lower than the first predetermined cutoff value; determining a second score based on the histological grade of the NET, wherein the second score is 1 when the NET is designated as a high grade, or the second score is 0 when the NET is designated as a low grade; calculating a third score based on the following formula: third score = 39.22787-40.80341*(first score)-18.441*(second score); and when the third score is equal to or greater than the predetermined cutoff value, administering PRRT to the subject.

[0080] The present disclosure provides a method of treating a subject with peptide receptor radiation therapy (PRRT), wherein the subject has a neuroendocrine tumor (NET), the method comprising: determining the expression levels of at least 12 biomarkers from the test sample by contacting the test sample from the subject with a plurality of reagents that specifically detect the expression of at least 12 biomarkers, wherein the 12 biomarkers include ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3, TECPR2, and ALG9; and normalizing the expression level of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3, TECPR2 to the expression level of ALG9, thereby obtaining an expression level of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3, TECPR2, and ALG9. The invention relates to a method for treating a subject with NETs of the invention, wherein the method comprises the steps of: determining a standardized expression level of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3 and TECPR2; summing the standardized expression levels of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3 and TECPR2 to obtain a total expression level; determining a first score, wherein the first score is 1 when the total expression level is equal to or greater than a first predetermined cutoff value, or the first score is 0 when the total expression level is lower than the first predetermined cutoff value; determining a second score based on the histological grade of the NET, wherein the second score is 1 when the NET is designated as a high grade, or the second score is 0 when the NET is designated as a low grade; calculating a third score based on the following formula: third score=39.22787-40.80341*(first score)-18.441*(second score); and administering PRRT to the subject when the third score is equal to or greater than the predetermined cutoff value, or administering an alternative treatment modality to the subject when the third score is less than the predetermined cutoff value.

[0081] The present disclosure provides a method of treating a subject with peptide receptor radiation therapy (PRRT), wherein the subject has a neuroendocrine tumor (NET), the method comprising: determining the expression level of each of at least 12 biomarkers from the test sample by contacting the test sample from the subject with a plurality of reagents that specifically detect the expression of at least 12 biomarkers, wherein the 12 biomarkers include ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3, TECPR2, and ALG9; The expression level of each of NK2, PLD3, NAP1L1, NOL3 and TECPR2 is normalized to the expression level of ALG9 to obtain the normalized expression level of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3 and TECPR2; the normalized expression levels of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3 and TECPR2 are summed to obtain the total expression level; and when the total expression level is equal to or greater than a predetermined cutoff value, PRRT is administered to the subject.

[0082] The present disclosure provides a method of treating a subject with peptide receptor radiation therapy (PRRT), wherein the subject has a neuroendocrine tumor (NET), the method comprising: determining the expression level of each of at least 12 biomarkers from the test sample by contacting the test sample from the subject with a plurality of reagents that specifically detect the expression of at least 12 biomarkers, wherein the 12 biomarkers include ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3, TECPR2, and ALG9; , NOL3 and TECPR2 to the expression level of ALG9, thereby obtaining a standardized expression level of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3 and TECPR2; summing the standardized expression levels of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3 and TECPR2 to obtain a total expression level; and administering PRRT to the subject when the total expression level is equal to or greater than a predetermined cutoff value, or administering an alternative treatment modality to the subject when the total expression level is less than a predetermined cutoff value.

[0083] The present disclosure provides a method of treating a subject with peptide receptor radiation therapy (PRRT), wherein the subject has a low-grade or high-grade neuroendocrine tumor (NET), the method comprising: determining the expression level of each of at least 12 biomarkers from the test sample by contacting the test sample from the subject with a plurality of reagents that specifically detect the expression of at least 12 biomarkers, wherein the 12 biomarkers include ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3, TECPR2, and ALG9; 2. The expression level of each of PANK2, PLD3, NAP1L1, NOL3 and TECPR2 is normalized to the expression level of ALG9 to obtain the standardized expression level of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3 and TECPR2; the standardized expression levels of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3 and TECPR2 are summed to obtain the total expression level; and when the total expression level is equal to or greater than a predetermined cutoff value, PRRT is given to the subject.

[0084] The present disclosure provides a method of treating a subject with peptide receptor radiation therapy (PRRT), wherein the subject has a low-grade or high-grade neuroendocrine tumor (NET), the method comprising: determining the expression level of each of at least 12 biomarkers from the test sample by contacting the test sample from the subject with a plurality of reagents that specifically detect the expression of at least 12 biomarkers, wherein the 12 biomarkers include ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3, TECPR2, and ALG9; The expression level of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3 and TECPR2 is normalized to the expression level of ALG9 to obtain a normalized expression level of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3 and TECPR2; the normalized expression levels of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3 and TECPR2 are summed to obtain a total expression level; and when the total expression level is equal to or greater than a predetermined cutoff value, administering PRRT to the subject, or when the total expression level is less than a predetermined cutoff value, administering an alternative treatment modality to the subject.

[0085] The present disclosure provides a method for treating a subject with peptide receptor radiation therapy (PRRT), wherein the subject suffers from a low-grade or high-grade neuroendocrine tumor (NET), the method comprising: determining the expression level of each of at least 9 biomarkers from the test sample by contacting the test sample from the subject with a plurality of reagents that specifically detect the expression of at least 9 biomarkers, wherein the 9 biomarkers include ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, and ALG9; The expression level of each of RAF-1, ATP6V1H, OAZ2, PANK2 and PLD3 is normalized to the expression level of ALG9 to obtain the standardized expression level of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2 and PLD3; the standardized expression level of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2 and PLD3 is summed to obtain the total expression level; and when the total expression level is equal to or greater than a predetermined cutoff value, PRRT is administered to the subject.

[0086] The present disclosure provides a method for treating a subject with peptide receptor radiation therapy (PRRT), wherein the subject has a low-grade or high-grade neuroendocrine tumor (NET), the method comprising: determining the expression level of each of at least 9 biomarkers from the test sample by contacting the test sample from the subject with a plurality of reagents that specifically detect the expression of at least 9 biomarkers, wherein the 9 biomarkers include ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, and ALG9; The expression level of each of AZ2, PANK2 and PLD3 is normalized to the expression level of ALG9 to obtain a normalized expression level of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2 and PLD3; the normalized expression levels of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2 and PLD3 are summed to obtain a total expression level; and when the total expression level is equal to or greater than a predetermined cutoff value, PRRT is administered to the subject, or when the total expression level is less than a predetermined cutoff value, an alternative treatment modality is administered to the subject.

[0087] In the methods of the present disclosure, administering PRRT to a subject may include administering a PRRT based on 177Lu's PRRT. Based on 177 Lu's PRRT can be 177 Lu-DOTA-Tyr 3 -Thr 8 -Octreotide (Lutathera).

[0088] In the methods of the present disclosure, about 7.4 GBq (200 mCi) may be administered about once every 8 weeks. 177 Lu-DOTA-Tyr 3 -Thr 8 - Octreotide, for a total of about 4 doses. Can be given about once every 8 weeks at a dose of about 6.5 GBq 177 Lu-DOTA-Tyr 3 -Thr 8 - Octreotide, for a total of about 4 doses. Can be given about once every 8 weeks at a dose of about 4.6 GBq 177 Lu-DOTA-Tyr 3 -Thr 8 - Octreotide, for a total of about 4 doses. Can be given about once every 8 weeks at a dose of about 3.2 GBq (100 mCi) 177 Lu-DOTA-Tyr 3 -Thr 8 - Octreotide, for a total of about 4 doses. Can be given about once every 8 weeks at a dose of about 3.7 GBq 177 Lu-DOTA-Tyr 3 -Thr 8 -Octreotide, continued for a total of about 4 doses.

[0089] In the methods of the present disclosure, PRRT can be administered intravenously. Alternatively, PRRT can be administered intra-arterially.

[0090] In the method disclosed herein, based on 177 Lu-based PRRT can be given intravenously. 177 Lu's PRRT can be given intra-arterially.

[0091] In the methods of the present disclosure, alternative treatment modalities may include administering chemotherapy to a subject. Alternative treatment modalities may include administering immunotherapy to a subject. Alternative treatment modalities may include administering radiotherapy to a subject. Alternative treatment modalities may include administering a combination of PRRT and chemotherapy to a subject. Alternative treatment modalities may include administering a combination of PRRT and immunotherapy to a subject. Alternative treatment modalities may include administering a combination of PRRT and radiotherapy to a subject. Alternative treatment modalities may include administering a combination of PRRT, immunotherapy, and chemotherapy to a subject. Alternative treatment may include administering a combination of PRRT, immunotherapy, chemotherapy, and radiotherapy to a subject. Alternative treatment modalities may include administering a combination of immunotherapy and chemotherapy to a subject.

[0092] Immunotherapy may include administering a checkpoint inhibitor. Checkpoint inhibitors may include antibodies. Checkpoint inhibitors include, but are not limited to, anti-CTLA4 antibodies, anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-A2AR antibodies, anti-B7-H3 antibodies, anti-B7-H4 antibodies, anti-BTLA antibodies, anti-IDO antibodies, anti-KIR antibodies, anti-LAG3 antibodies, anti-TIM3 antibodies, and anti-VISTA (V-domain Ig inhibitor of T cell activation) antibodies.

[0093] Anti-CTLA4 antibodies may include, but are not limited to, ipilimumab, tremelimumab, and AGEN-1884. Anti-PD-1 antibodies include, but are not limited to, pembrolizumab, nivolumab, pidilizumab, cemiplimab, REGN2810, AMP-224, MEDI0680, PDR001, and CT-001. Anti-PD-L1 antibodies include, but are not limited to, atezolizumab, avelumab, and durvalumab. Anti-CD137 antibodies include, but are not limited to, urelumab. Anti-B7-H3 antibodies include, but are not limited to, MGA271. Anti-KIR antibodies include, but are not limited to, Lirilumab. Anti-LAG3 antibodies include, but are not limited to, BMS-986016.

[0094] The term "immunotherapy" may refer to activating immunotherapy or suppressing immunotherapy. As will be appreciated by those skilled in the art, activating immunotherapy refers to the use of therapeutic agents that induce, enhance or promote immune responses (including, for example, T cell responses), while suppressing immunotherapy refers to the use of therapeutic agents that interfere, suppress or inhibit immune responses (including, for example, T cell responses). Activating immunotherapy may include the use of checkpoint inhibitors. Activating immunotherapy may include administering to a subject a therapeutic agent that activates stimulatory checkpoint molecules. Stimulatory checkpoint molecules include, but are not limited to, CD27, CD28, CD40, CD122, CD137, OX40, GITR, and ICOS. Therapeutic agents that activate stimulatory checkpoint molecules include, but are not limited to, MEDI0562, TGN1412, CDX-1127, and lipocalin.

[0095] The term "antibody" herein is used in the broadest sense and encompasses a variety of antibody structures, including, but not limited to, monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments, as long as they exhibit the desired antigen-binding activity. An antibody that binds to a target refers to an antibody that is capable of binding to a target with sufficient affinity so that the antibody can be used as a diagnostic and / or therapeutic agent for targeting the target. In one embodiment, the extent of binding of an anti-target antibody to an unrelated, non-target protein is less than about 10% of the binding of the antibody to the target, as measured, for example, by a radioimmunoassay (RIA) or a biacore assay. In certain embodiments, the dissociation constant (Kd) of an antibody that binds to a target is <1 μM, <100 nM, <10 nM, <1 nM, <0.1 nM, <0.01 nM, or <0.001 nM (e.g., 10 8 M or smaller, e.g. 10 8 M-10 13 M, for example 10 9 M-10 13 M). In certain embodiments, the anti-target antibody binds to a target epitope that is conserved between different species.

[0096] "Blocking antibodies" or "antagonistic antibodies" are antibodies that partially or completely block, inhibit, interfere with, or neutralize the normal biological activity of the antigen to which it binds. For example, antagonistic antibodies can block signal transduction through immune cell receptors (e.g., T cell receptors), thereby restoring the functional response of T cells to antigen stimulation (e.g., proliferation, cytokine production, target cell killing) from a dysfunctional state.

[0097] "Agonistic antibodies" or "activating antibodies" are antibodies that simulate, promote, stimulate or enhance the normal biological activity of the antigen to which they bind. Agonistic antibodies can also enhance or initiate signal transduction through the antigen to which they bind. In some embodiments, agonistic antibodies cause or activate signal transduction in the absence of a natural ligand. For example, agonistic antibodies can increase memory T cell proliferation, increase cytokine production by memory T cells, inhibit regulatory T cell function, and / or inhibit regulatory T cells from inhibiting effector T cell function, such as effector T cell proliferation and / or cytokine production.

[0098] "Antibody fragment" refers to a molecule other than an intact antibody, which comprises a portion of an intact antibody that binds to the antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2; diabodies; linear antibodies; single-chain antibody molecules (e.g., scFv); and multispecific antibodies formed from antibody fragments.

[0099] Administration of chemotherapy to a subject may include administration of a therapeutically effective dose of at least one chemotherapeutic agent. Chemotherapeutic agents include, but are not limited to, 13-cis retinoic acid, 2-CdA, 2-chlorodeoxyadenosine, 5-azacytidine, 5-fluorouracil, 5-FU, 6-mercaptopurine, 6-MP, 6-TG, 6-thioguanine, Abemaciclib, Abiraterone acetate, Abraxane, Accutane, Actinomycin-D, Adcetris, Ado-Trastuzumab Emtansine、Adriamycin、Adrucil、Afatinib、Afinitor、Agrylin、Ala-Cort、Aldesleukin、Alemtuzumab、Alecensa、Alectinib、Alimta、Alitretinoin、Alkaban-AQ、Alkeran、All-transretinoic Acid、Alpha-interferon Interferon、Altretamine、Alunbrig、Amethopterin、Amifostine、Aminoglutethimide、Anagrelide、Anandron、Anastrozole、Apalutamide、Arabinosylcytosine、Ara-C、Aranesp、Aredia、Arimidex、Aromasin、Arranon、Arsenic Trioxide、Arzerra、Asparaginase、atezolizumab、Atra、Avastin、Avelumab、AxicabtageneCiloleucel, Axitinib, Azacitidine, Bavencio, Bcg, Beleodaq, Belinostat, Bendamustine, Bendeka, Besponsa, Bevacizumab, Bexarotene, Bexxar, Bicalutamide, Bicnu, Blenoxane, Bleomycin, Blinatumomab, Blincyto, Bortezomib, Bosulif, Bosutinib, Brentuximab Vedotin, Brigatinib, Busulfan, Busulfex, C225, Cabazitaxel, Cabozantinib, Calcium Leucovorin, Campath, Camptosar, Camptothecin-11, Capecitabine, Caprelsa, Carac, Carboplatin, Carfilzomib, Carmustine, Carmustine Wafers Wafer、Casodex、CCI-779、Ccnu、Cddp、Ceenu、Ceritinib、Cerubidine、Cetuximab、Chlorambucil、Cisplatin、Citrovorum Factor、Cladribine、Clofarabine、Clolar、Cobimetinib、Cometriq、Cortisone、Cosmegen、Cotellic、Cpt-11、Crzotinib、Cyclophosphamide、Cyramza、Cytadren、Cytarabine、Cytarabine liposomeLiposomal, Cytosar-U, Cytoxan, Dabrafenib, Dacarbazine, Dacogen, Dactinomycin, Daratumumab, Darbepoetin Alfa, Darzalex, Dasatinib, Daunomycin, Daunorubicin, Daunorubicin Cytarabine (liposomal), daunorubicin hydrochloride, Daunorubicin liposomal Liposomal, DaunoXome, Decadron, Decitabine, Degarelix, Delta-Cortef, Deltasone, Denileukin Diftitox, Denosumab, DepoCyt, Dexamethasone, Dexamethasone Acetate, Dexamethasone Sodium Phosphate, Dexasone, Dexrazoxane, Dhad, Dic, Diodex, Docetaxel, Doxil, Doxorubicin, Doxorubicin Liposomal Liposomal, Droxia, DTIC, Dtic-Dome, Duralone, Durvalumab, Eculizumab, Efudex, Ellence, Elotuzumab, Eloxatin, Elspar, Eltrombopag, Emcyt, Empliciti, Enasidenib, Enzalutamide, Epirubicin, Epoetin alfaAlfa), Erbitux, Eribulin, Erivedge, Erleada, Erlotinib, Erwinia L-asparaginase L-asparaginase、Estramustine、Ethyol、Etopophos、Etopophos、Etoposide Phosphate、Eulexin、Everolimus、Evista、Exemestane、Fareston、Farydak、Faslodex、Femara、Filgrastim、Firmagon、Floxuridine、Fludara、Fludarabine、Fluoroplex、Fluorouracil、Fluorouracil Cream、Fluoxymesterone、Flutamide、Folinic Acid Acid, Folotyn, Fudr, Fulvestrant, G-Csf, Gazyva, Gefitinib, Gemcitabine, Gemtuzumab ozogamicin, Gemzar, Gilotrif, Gleevec, Gleostine, Gliadel Wafer, Gm-Csf, Goserelin, Granix, Granulocyte-Colony Stimulating Factor, Granulocyte Macrophage Colony Stimulating Factor Factor), Halaven, Halotestin, Herceptin, Hexadrol, Hexalen, Hexamethylmelamine, Hmm, Hycamtin, Hydrea, Hydrocortisone acetateAcetate, Hydrocortisone, Hydrocortisone Sodium Phosphate, Hydrocortisone Sodium Succinate, Hydrocortone Phosphate, Hydroxyurea, Ibrance, Ibritumomab, Ibritumomab Tiuxetan, Ibrutinib, Iclusig, Idamycin, Idarubicin, Idelalisib, Idhifa, Ifex, IFN-α, Ifosfamide, IL-11, IL-2, Imbruvica, Imatinib mesylate mesylate、Imfinzi、Imidazole Carboxamide、Imlygic、Inlyta、Inotuzumab Ozogamicin、Interferon-α、Interferon α-2b (PEG conjugate), Interleukin-2、Interleukin-11、IntronA (interferon alpha-2b), Ipilimumab, Iressa, Irinotecan, Irinotecan (liposomal), Isotretinoin, Istodax, Ixabepilone, Ixazomib, Ixempra, Jakafi, Jevtana, Kadcyla, Keytruda, Kidrolase, Kisqali, Kymriah, Kyprolis, Lanacort, Lanreotide, Lapatinib, Latruvo Lartruvo, L-Asparaginase, Lbrance, Lcr, Lenalidomide, Lenvatinib, Lenvima, Letrozole, Leucovorin, Leukeran, Leukine, Leuprolide, Leurocristine, Leustatin, Liposomal Ara-C, Liquid Pred, Lomustine, Lonsurf, L-PAM, L-Sarcolysin, Lupron, Lupron Depot Suspension Depot, Lynparza, Marqibo, Matulane, Maxidex, Mechlorethamine, Mechlorethamine Hydrochloride, Medralone, Medrol, Megace, Megestrol, Megestrol Acetate, Mekinist, Mercaptopurine, Mesna, Mesnex, Methotrexate, Methotrexate SodiumSodium, Methylprednisolone, Meticorten, Midostaurin, Mitomycin, Mitomycin-C, Mitoxantrone, M-Prednisolone, MTC, MTX, Mustargen, Mustine, Mutamycin, Myleran, Mylocel, Mylotarg, Navelbin e), Necitumumab, Nelarabine, Neosar, Neratinib, Nerlynx, Neulasta, Neumega, Neupogen, Nexavar, Nilandron, Nilotinib, Nilutamide, Ninlaro, Nipent, Niraparib, Nitrogen Mustard, Nivolumab, Nolvadex, Novantrone, Nplate, Obinutuzumab, Octreotide, Octreotide acetate Acetate, Odomzo, Ofatumumab, Olaparib, Olaratumab, Omacetaxine, Oncospar, Oncovin, Onivyde, Ontak, Onxal, Opdivo, Oprelvekin, Orapred, Orasone, Osimertinib, Otrexup, Oxaliplatin, Paclitaxel, Paclitaxelprotein-bound), Palbociclib, Pamidronate, Panitumumab, Panobinostat, Panretin, Paraplatin, Pazopanib, Pediapred, PegInterferon, Pegaspargase, Pegfilgrastim, Peg-Intron, PEG-L-asparaginase, Pembrolizumab, Pemetrexed, Pentostatin, Perjeta, Pertuzumab, Phenylalanine Mustard, Platinol, Platinol-AQ, Pomalidomide, Pomalyst, Ponatinib, Portrazza, Pralatrexate, Prednisolone, Prednisone, Prelone, Procarbazine, Procrit, Proleukin, Prolia, Prolifeprospan 20 with carmustine implant, Promacta, Provenge, Purinethol, Radium 223 dichloride 223Dichloride), Raloxifene, Ramucirumab, Rasuvo, Regorafenib, Revlimid, Rheumatrex, Ribociclib, Rituxan, Rituxan Hycela, Rituximab, Rituximab HyaluronidaseHyalurodinase, Roferon-A (interferon α-2a), Romidepsin, Romiplostim, Rubex, Rubidomycin Hydrochloride, Rubraca, Rucaparib, Ruxolitinib, Rydapt, Sandostatin, Sandostatin LAR LAR), Sargramostim, Siltuximab, Sipuleucel-T, Soliris, Solu-Cortef, Solu-Medrol, Somatuline, Sonidegib, Sorafenib, Sprycel, Sti-571, Stivarga, Streptozocin, SU11248, Sunitinib, Sutent, Sylvant, Synribo, Tafinlar, Tagrisso, Talimogene Laherparepvec, Tamoxifen, Tarceva, Targretin, Tasigna, Taxol, Taxotere, Tecentriq, Temodar, Temozolomide, Temsirolimus, Teniposide, Tespa, Thalidomide, Thalomid, TheraCys, Thioguanine, Thioguanine tabletsTabloid, Thiophosphoramide, Thioplex, Thiotepa, Tice, Tisagenlecleucel, Toposar, Topotecan, Toremifene, Torisel, Tositumomab, Trabectedin, Trametinib, Trastuzumab, Treanda, Trelstar, Tretinoin, Trexall, Trifluridine / Tipiracil, Triptorelin pamoate pamoate), arsenic trioxide (Trisenox), thiotepa (Tspa), T-VEC, Tykerb, valrubicin, Valstar, vandetanib, VCR, Vectibix, vinblastine (Velban), Velcade, Vemurafenib, Venclexta, Venetoclax, VePesid, Verzenio, Vesanoid, leuprorelin acetate implant (Viadur), Vidaza, Vinblastine, Vinblastine Sulfate, Vincristine Sulfate Injection (VincasarPfs), Vincristine, Vincristine Liposomal (Vincristine Liposomal, Vinorelbine, Vinorelbine Tartrate, Vismodegib, Vlb, VM-26, Vorinostat, Votrient, VP-16, Vumon, Vyxeos, XalkoriCapsules, Xeloda, Xgeva, Xofigo, Xtandi, Yervoy, Yescarta, Yondelis, Zaltrap, Zanosar, Zarxio, Zejula, Zelboraf, Zevalin, Zinecard, Ziv-aflibercept, Zoladex, Zoledronic Acid, Zolinza, Zometa, Zydelig, Zykadia, Zytiga, or any combination thereof.

[0100] The biomarker / housekeeping sequence information is detailed in Table 1. The position of the amplicon identified for each biomarker is underlined.

[0101] Table 1. definition The articles "a" and "an" used in this disclosure refer to one or to more than one (ie, to at least one) of the grammatical object of the article. For example, "an element" means one element or more than one element.

[0102] Unless otherwise stated, the term "and / or" is used in this disclosure to mean "and" or "or".

[0103] The terms "polynucleotide" and "nucleic acid molecule" as used herein are used interchangeably, meaning a polymeric form of nucleotides (i.e., ribonucleotides or deoxynucleotides or modified forms of either type of nucleotides) of at least 10 bases or base pairs in length, and meaning single-stranded and double-stranded forms including DNA. The nucleic acid molecules or nucleic acid sequences used as probes in microarray analysis as used herein preferably comprise nucleotide chains, more preferably DNA and / or RNA. In other embodiments, the nucleic acid molecules or nucleic acid sequences comprise other types of nucleic acid structures, such as DNA / RNA helices, peptide nucleic acids (PNAs), locked nucleic acids (LNAs) and / or ribozymes. Therefore, the term "nucleic acid molecule" as used herein also encompasses chains comprising non-natural nucleotides, modified nucleotides and / or non-nucleotide structural units that exhibit the same functions as natural nucleotides.

[0104] As used herein, the terms "hybridize," "hybridizing," "hybridizes," and the like used in the context of polynucleotides refer to conventional hybridization conditions, such as hybridization in 50% formamide / 6XSSC / 0.1% SDS / 100 μg / ml ssDNA, wherein the hybridization temperature is above 37 degrees, and the temperature of washing with 0.1XSSC / 0.1% SDS is above 55°C, and preferably stringent hybridization conditions.

[0105] As used herein, the term "standardization" or "normalizer" refers to expressing differential values ​​in terms of a standard value to adjust for effects due to technical variations in sample handling, sample preparation, and measurement methods rather than biological variations in the concentration of biomarkers in the sample. For example, when measuring the expression of a differentially expressed protein, the absolute value of the expression of that protein can be expressed in terms of the absolute value of the expression of a standard protein whose expression is substantially constant.

[0106] The terms "diagnosis" and "diagnostics" also encompass the terms "prognosis" and "prognostics", respectively, as well as the application of such procedures over two or more time points to monitor the diagnosis and / or prognosis over time, and statistical modeling based thereon. In addition, the term diagnosis includes: a. prediction (determining whether a patient will likely develop aggressive disease (hyperproliferative / aggressive)), b. prognosis (predicting whether a patient will likely have a better or worse outcome at a preselected time in the future); c. treatment selection, d. therapeutic drug monitoring, and e. recurrence monitoring.

[0107] As used herein, the term "providing" with respect to a biological sample refers to obtaining a biological sample directly or indirectly from a subject. For example, "providing" may refer to the act of obtaining a biological sample directly from a subject (e.g., by drawing blood, biopsy, lavage, etc.). Similarly, "providing" may refer to the act of obtaining a biological sample indirectly. For example, providing may refer to the act of a laboratory receiving a sample from a party that directly obtains the sample, or to the act of obtaining a sample from an archive.

[0108] "Accuracy" refers to the closeness of agreement between a measured or calculated quantity (a test-reported value) and its actual (or true) value. Clinical accuracy is related to the proportion of true results (true positives (TP) or true negatives (TN)) relative to misclassified results (false positives (FP) or false negatives (FN)) and can be expressed as sensitivity, specificity, positive predictive value (PPV) or negative predictive value (NPV), or as a measure such as likelihood, odds ratio, etc.

[0109] As used herein, the term "biological sample" refers to any sample of biological origin that may contain one or more biomarkers. Examples of biological samples include tissues, organs, or body fluids, such as whole blood, plasma, serum, tissue, lavage fluid, or any other sample used to detect disease.

[0110] The term "subject" as used herein refers to a mammal, preferably a human. The terms "subject" and "patient" are used interchangeably herein.

[0111] As used herein, "treating" or "treatment" with respect to a disorder may mean preventing the disorder, slowing the onset or rate of development of the disorder, reducing the risk of developing the disorder, preventing or delaying the development of symptoms associated with the disorder, reducing or stopping symptoms associated with the disorder, causing complete or partial regression of the disorder, or some combination thereof.

[0112] The level of a biomarker may change due to treatment of a disease. Changes in the level of a biomarker can be measured by the present disclosure. Changes in the level of a biomarker can be used to monitor the progression of a disease or treatment.

[0113] The term "stable disease" refers to a diagnosis of the presence of NETs, ​​however, the NETs have been treated and remain stable, ie, not progressive, as determined by imaging data and / or best clinical judgment.

[0114] The term "progressive disease" refers to the diagnosis of a state in which a highly active NET is present, i.e., the NET has not been treated and is unstable, or has been treated and is not responsive to treatment, or has been treated and active disease persists, as determined by imaging data and / or best clinical judgment.

[0115] The terms "effective amount" and "therapeutically effective amount" of an agent or compound are used in the broadest sense to refer to a non-toxic but sufficient amount of the active agent or compound to provide the desired effect or benefit.

[0116] The term "benefit" is used in the broadest sense and refers to any desired effect, and specifically includes clinical benefit as defined herein. Clinical benefit can be measured by evaluating various endpoints, such as inhibiting the progression of the disease to a certain extent, including slowing down and completely stopping; reducing the number of disease attacks and / or symptoms; reducing the size of lesions; inhibiting (i.e., reducing, slowing down or completely stopping) the infiltration of disease cells into adjacent peripheral organs and / or tissues; inhibiting (i.e., reducing, slowing down or completely stopping) the spread of the disease; reducing autoimmune reactions, which may (but not necessarily) lead to the regression or ablation of the disease lesion; alleviating one or more symptoms associated with the disorder to a certain extent; increasing the length of disease-free survival after treatment, such as progression-free survival; improving overall survival; higher response rate; and / or reducing the mortality rate at a given time point after treatment.

[0117] The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is generally characterized by uncontrolled cell growth. The definition includes both benign and malignant cancers. Examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia. More specific examples of such cancers include adrenocortical carcinoma, bladder urothelial carcinoma, invasive breast cancer, cervical squamous cell carcinoma, endocervical adenocarcinoma, bile duct carcinoma, colon adenocarcinoma, lymphoid tumors diffuse large B-cell lymphoma, esophageal cancer, glioblastoma multiforme, head and neck squamous cell carcinoma, kidney chromophobe cell carcinoma, renal clear cell carcinoma, renal papillary cell carcinoma, acute myeloid leukemia, brain low-grade glioma, hepatocellular carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, mesothelioma, ovarian serous cystadenocarcinoma, pancreatic adenocarcinoma, pheochromocytoma, paraganglioma, prostate adenocarcinoma, rectal adenocarcinoma, sarcoma, skin melanoma, gastric adenocarcinoma, testicular germ cell tumor, thyroid cancer, thymoma, uterine carcinosarcoma, uveal melanoma. Other examples include breast cancer, lung cancer, lymphoma, melanoma, liver cancer, colorectal cancer, ovarian cancer, bladder cancer, kidney cancer, or gastric cancer. Other examples of cancer include neuroendocrine cancer, non-small cell lung cancer (NSCLC), small cell lung cancer, thyroid cancer, endometrial cancer, bile duct cancer, esophageal cancer, anal cancer, salivary gland cancer, vulvar cancer, or cervical cancer.

[0118] The term "tumor" refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all precancerous and cancerous cells and tissues. The terms "cancer," "cancerous," "cell proliferative disorder," "proliferative disorder," and "tumor" as used herein are not mutually exclusive.

[0119] As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

[0120] Unless otherwise stated or obvious from the context, the term "or" as used herein should be construed as inclusive and encompasses both "or" and "and." Example

[0121] The present disclosure is further illustrated by the following examples, which should not be construed as limiting the present disclosure in scope or spirit to the specific procedures described herein. It should be understood that these examples are provided to illustrate certain embodiments and are not intended to limit the scope of the present disclosure. It should be further understood that various other embodiments, modifications thereof, and equivalent forms that may be presented to those skilled in the art may have to be resorted to without departing from the spirit of the present disclosure and / or the scope of the appended claims.

[0122] Example 1 Derivation of the PRRT Prediction Quotient (PPQ): An 8-marker gene panel with combined levels The PRRT prediction quotient (PPQ) includes the expression and tissue level of genes (Table 2) involved in growth factor expression / metabolism. It provides two biomarker outputs-"positive" (or predicted responders) and "negative" (or predicted non-responders). The model was developed from an initial cohort of 54 patients and then clinically validated in 4 independent cohorts (n=214).

[0123] Table 2. A two-step protocol (RNA isolation, cDNA production, and PCR) was used to measure the expression of growth factor (GF)-related genes (ARAF1, BRAF, KRAS, and RAF-1), genes involved in metabolism (M) (ATP6V1H, OAZ2, PANK2, and PLD3), and optionally genes involved in proliferation (P) (NAP1L1, NOL3, and TECPR2). The expression levels were normalized to ALG9. In some embodiments, a total GF+M value ≥5.9 was scored as "1", and a value <5.9 was scored as "0". In some embodiments, a total GF+M+P value ≥10.9 was scored as "1", and a value <10.9 was scored as "0". According to histology, low grade (G1 / G2, well-differentiated or bronchial typical or atypical carcinoid) was scored as "0"; high grade (G3, poorly differentiated) was scored as "1". These data were combined into a predictive model using logistic regression classification, and a score was generated for each sample. The PPQ of the sample is derived from: PPQ = 39.22787-40.80341*(total GF+M gene expression)-18.441*(rank) or PPQ = 39.22787-40.80341*(total GF+M+P gene expression)-18.441*(rank) A binary output can be generated from the model.

[0124] (1) Responders are individuals predicted by the PPQ to have stable disease or show a partial response. These are scored as biomarker “positive” and show a p-value < 0.5.

[0125] (2) Non-responders were defined as individuals who showed progressive disease at follow-up (PRRT failure). These were considered biomarker “negative” and showed a p value ≥ 0.5.

[0126] Table 3 provides five output examples.

[0127] Table 3. These are example outputs from the algorithm.

[0128] *Normalized gene expression of ARAF1, BRAF, KRAS and RAF-1; **Normalized gene expression of APT61VH, OAZ2, PANK2 and PLD3; ***Normalized gene expression of NAP1L1, NOL3 and TECPR2; & Low grade (G1 / G2, well-differentiated, or bronchial typical or atypical carcinoid); high grade (G3, poorly differentiated; $ Values ​​> 0.5 were classified as non-responders; and # R = responder (PPQ-positive); NR = non-responder (PPQ-negative).

[0129] The model has the following metrics: Chi 2 =41.6, DF=2, p<0.00001, Cox&Snell R 2 =0.537, Nagelkerke R 2 =0.722.

[0130] In the test population, the classifier was 94% accurate, including 97% responders and 91% non-responders.

[0131] The cohort was increased to 72 patients. PPQ accurately predicted responders at initial (100%) and final (100%) follow-up (Table 4). Non-responders were predicted in 65% (initial) and 84% (final) (Fishers, p = NS). Overall, 67 / 72 (93%) were correctly predicted at final follow-up. PRRT responders were predicted in 100% of cases and non-responders were predicted in 84% of cases (Table 4). Assessment of progression-free survival identified that mPFS was not obtained in responders predicted by PPQ. For those predicted to have no response, mPFS was 8 months. This is a significant difference (HR 36.4, p < 0.0001) ( Figure 1 ). The sensitivity of the test is 100% and the NPV is 100%.

[0132] The model has the following metrics: Chi 2 =41.6, DF=2, p<0.00001, Cox&Snell R 2 =0.537, Nagelkerke R 2 =0.722.

[0133] In the test population, the classifier was 94% accurate, including 97% responders and 91% non-responders.

[0134] The cohort was increased to 72 patients. PPQ accurately predicted responders at initial (100%) and final (100%) follow-up (Table 4). Non-responders were predicted in 65% (initial) and 84% (final) (Fishers, p = NS). Overall, 67 / 72 (93%) were correctly predicted at final follow-up. PRRT responders were predicted in 100% of cases and non-responders were predicted in 84% of cases (Table 4). Assessment of progression-free survival identified that mPFS was not obtained in responders predicted by PPQ. For those predicted to have no response, mPFS was 8 months. This is a significant difference (HR 36.4, p < 0.0001) ( Figure 1 ). The sensitivity of the test is 100% and the NPV is 100%.

[0135] Table 4. Predictive Accuracy of PPQ in the PRRT-treated Cohort In Table 4, *Follow-up was ∼6-9 months after the end of the last PRRT cycle; **Se = sensitivity, Sp = specificity, PPV = positive predictive value, NPV = negative predictive value.

[0136] Predicting response to PRRT Validation I (n=44): PPQ accurately predicted responders at follow-up with 97%. Predicted non-responders with 93% (final). Overall, 42 / 44 (95%) were correctly predicted (Table 4). Survival assessment identified that mPFS was not derived in those predicted to respond. For "non-responders", mPFS was 14 months (HR 17.7, p<0.0001) ( Figure 2 ). The test had a sensitivity of 97% and an NPV of 93%.

[0137] Validation II (n=42): PPQ accurately predicted responders at 94% at follow-up. Predicted non-responders at 100%. Overall, 40 / 42 (95%) were correctly predicted at final follow-up. Predicted PRRT responders at 95% and non-responders at 100% (Table 4). Survival assessment identified that mPFS was not derived in those expected to respond. For "non-responders", mPFS was 9.7 months (HR 92, p<0.0001) ( Figure 3 ). The test had a sensitivity of 94% and an NPV of 95%.

[0138] Specificity of PPQ - predicting response to non-radioactive somatostatin The PPQ was determined retrospectively in 28 patients treated with SSA alone. At follow-up, 15 (54%) had stable disease and 13 (46%) had progressive disease. The PPQ correctly predicted stable disease in 8 (53%) and progressive disease in 6 (47%, p = NS). Survival analysis identified no effect on PFS ( Figure 4 ). The sensitivity and NPV were 53% and 46%, respectively. The PPQ failed to predict the response to SSA.

[0139] Specificity of PPQ – as a prognostic marker The PPQ was retrospectively determined for 100 patients included in the registry. The entire group was analyzed regardless of treatment. At follow-up, 48 patients (48%) had stable disease and 52 patients (52%) developed progressive disease. The PPQ correctly predicted stable disease in 32 patients (67%) and progressive disease in 19 patients (37%, p=NS). Survival analysis identified no effect on PFS ( Figure 5 ). The sensitivity and NPV were 67% and 50%, respectively. During the follow-up period, PPQ failed to serve as a prognostic biomarker.

[0140] Demonstrated predictive utility for PRRT To demonstrate that a biomarker predicts treatment, studies should assess biomarker levels in those expected to benefit from treatment as well as in those not treated with the agent. Because biomarkers may have both predictive and prognostic characteristics, the association between biomarkers and outcomes needs to be assessed regardless of treatment.

[0141] Comparison of Kaplan-Meier survival curves (PFS) between each of these cohorts is presented in Fig. 6A (predicting “responders”) and Figure 6B (predicting "non-responders"). "Treatment effect" was only noted in those (validation I and validation II cohorts) whose biomarkers were "positive", i.e., predicted as "responders" and subjected to PRRT. Specifically, quantitative differences were noted in median PFS between the PRRT-treated and non-PRRT-treated groups (statistically significant, p<0.0001). This effect occurred regardless of whether it was "positive" for all biomarkers. In contrast, no difference in PFS was noted in the biomarker "negative" group. This effect was noted regardless of treatment. These data indicate that PPQ acts as a predictive marker.

[0142] The metrics used to idealize biomarkers are included in Figure 6C -D. The treatment effect was noted only in those treated and PPQ biomarker "positive" ( Figure 6C- these are two validation cohorts). It is important to emphasize that this particular example identifies an idealized biomarker that is not prognostic. This is highlighted by the similar survival curves in the biomarker positive and negative groups (not presented). Fig. 6A (biomarker positive) identified, the survival curves of the SSA treatment cohort and the registry cohort (both PRRT-naive -10 months) were similar Figure 6B There was no difference in the survival curves of the PRRT-treated cohort (biomarker negative - survival 10-15 months), confirming that PPQ is not prognostic.

[0143] Evaluation of PPQ-negative patients The clinical outcomes of patients identified as predicted non-responders to PRRT treatment based on the PPQ were further analyzed. PPQ-predicted non-responders treated with standard 4-cycle PRRT with lutetium octreotide showed a median PFS of 9 months, as Figure 7 In contrast, PPQ-predicted non-responders who underwent a personalized approach (where chemotherapy was added to the regimen) showed a longer PFS of 14 months, as shown in Figure 7 These data suggest that patients who were PPQ negative (predicting nonresponders) and received additional treatment responded better than those who received standard treatment. Therefore, PPQ can be used to identify patients who require additional agents (e.g., immune-related therapy or chemotherapy) to be used with PRRT to optimize outcomes.

[0144] References: 1. Bodei L, Kwekkeboom DJ, Kidd M, Modlin IM, Krenning EP. Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer. Semin NuclMed. 2016; 46: 225-238. doi: 210.1053 / j.semnuclmed.2015.1012.1003. 2.Reubi JC, Laissue J, Waser B, Horisberger U, Schaer JC. Expression of somatostatin receptors in normal, inflamed, and neoplastic humangastrointestinal tissues. Ann N Y Acad Sci. 1994; 733:122-137. 3.Bodei L,Kwekkeboom DJ,Kidd M,Modlin IM,Krenning EP.RadiolabeledSomatostatin Analogue Therapy OfGastroenteropancreatic Cancer.SeminNuclMed.2016;46:225-238. 4.Cives M,Strosberg J.Radionuclide Therapy for NeuroendocrineTumors.Curr Oncol Rep.2017;19:9. 5.Brabander T,van der Zwan WA,Teunissen JJM,et al.Long-Term Efficacy,Survival,and Safety of[177Lu-DOTA0,Tyr3]octreotate in Patients withGastroenteropancreatic and Bronchial Neuroendocrine Tumors.ClinCancerRes.2017;23:4617-4624. 6.Sansovini M,Severi S,Ambrosetti A,et al.Treatment with theradiolabelled somatostatin analog Lu-DOTATATE for advanced pancreaticneuroendocrine tumors.Neuroendocrinology.2013;97:347-354.doi:310.1159 / 000348394.Epub 000342013May 000348322. 7.Ezziddin S,Khalaf F,Vanezi M,et al.Outcome ofpeptide receptorradionuclide therapy with177Lu-octreotate in advanced grade 1 / 2pancreaticneuroendocrine tumours.Eur J Nucl Med Mol Imaging.2014;41:925-933. 8.Mariniello A,Bodei L,Tinelli C,et al.Long-term results of PRRT inadvanced bronchopulmonary carcinoid.Eur JNucl MedMol Imaging.2016;43:441-452. 9.Strosberg J,El-Haddad G,Wolin E,et al.Phase 3Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.N Engl JMed.2017;376:125-135. 10.Kwekkeboom DJ,Kam BL,van Essen M,et al.Somatostatin-receptor-basedimaging and therapyofgastroenteropancreatic neuroendocrine tumors.EndocrRelatCancer.2010;17:R53-73.11.Charoenpitakchai M,Liu E,Zhao Z,et al.In livermetastases from small intestinal neuroendocrine tumors,SSTR2Aexpression isheterogeneous.VirchowsArch.2017;470:545-552.12.Oksuz MO,Winter L,PfannenbergC,et al.Peptide receptor radionuclide therapy of neuroendocrine tumors with(90)Y-DOTATOC:is treatment response predictable bypre-therapeutic uptake of(68)Ga-DOTATOC?Diagn Interv Imaging.2014;95:289-300. 13.Gabriel M,Oberauer A,Dobrozemsky G,et al.68Ga-DOTA-Tyr3-octreotidePET for assessingresponse to somatostatin-receptor-mediated radionuclidetherapy.J Nucl Med.2009;50:1427-1434.14.Blaickner M,Baum RP.Relevance of PETfor pretherapeutic prediction of doses in peptidereceptor radionuclidetherapy.PET Clin.2014;9:99-112. 15.Oberg K,Krenning E,Sundin A,et al.A Delphic consensus assessment:imaging andbiomarkers in gastroenteropancreatic neuroendocrine tumor diseasemanagement.Endocr Connect.2016;5:174-187. 16.Yang Z,Tang LH,Klimstra DS.Effect of Tumor Heterogeneity on theAssessment of Ki67Labeling Index in Well-differentiated Neuroendocrine TumorsMetastatic to the Liver:Implicationsfor Prognostic Stratification.Am J SurgPathol.2011;35:853-860. 17.Ezziddin S,Attassi M,Yong-Hing CJ,et al.Predictors of long-termoutcome in patients withwell-differentiated gastroenteropancreaticneuroendocrine tumors after peptide receptorradionuclide therapy with 177Lu-octreotate.J Nucl Med.2014;55:183-190.doi:110.2967 / jnumed.2113.125336.Epub122014 Jan 125316. 18.Thang SP,Lung MS,Kong G,et al.Peptide receptor radionuclidetherapy(PRRT)in EuropeanNeuroendocrine Tumour Society(ENETS)grade 3(G3)neuroendocrine neoplasia(NEN)-asingle-institution retrospective analysis.EurJ Nucl Med Mol Imaging.2017;12:017-3821. 19.Walenkamp A,Crespo G,Fierro Maya F,et al.Hallmarks ofgastrointestinal neuroendocrinetumours:implications for treatment.EndocrRelat Cancer.2014;21:R445-460.doi:410.1530 / ERC-1514-0106. 20.Wang E,Zaman N,McGee S,Milanese JS,Masoudi-Nejad A,O'Connor-McCourt M.Predictive genomics:A cancer hallmark network framework forpredicting tumor clinicalphenotypes using genome sequencing data.Semin CancerBiol.2014;18:00050-00059. 21.Oxnard GR,Paweletz CP,Kuang Y,et al.Noninvasive detection ofresponse and resistance inEGFR-mutant lung cancer using quantitative next-generation genotyping ofcell-free plasma DNA.Clin Cancer Res.2014;20:1698-1705.doi:1610.1158 / 1078-0432.CCR-1613-2482.Epub 2014 Jan1615. 22.Kidd M,Drozdov I,Modlin I.Blood and tissue neuroendocrine tumorgene cluster analysiscorrelate,define hallmarks and predict diseasestatus.Endocr Relat Cancer.2015;22:561-575.doi:510.1530 / ERC-1515-0092.Epub2015 Jun 1532. 23.Li SC,Essaghir A,Martijn C,et al.Global microRNA profiling ofwell-differentiated smallintestinal neuroendocrine tumors.Mod Pathol.2013;26:685-696.doi:610.1038 / modpathol.2012.1216.Epub 2013 Jan 1018. 24.Modlin I,Drozdov I,Kidd M.The Identification of gut neuroendocrinetumor disease by multiple synchronous transcript analysis inblood.PlosOne.2013;e63364. 25.Bodei L,Kidd M,Modlin IM,et al.Measurement of circulatingtranscripts and gene cluster analysis predicts and defines therapeuticefficacy ofpeptide receptor radionuclide therapy(PRRT)in neuroendocrinetumors.Eur J Nucl Med Mol Imaging.2016;43:839-851.doi:810.1007 / s00259-00015-03250-z.Epub 02015Nov 00223. 26.Califano A,Alvarez MJ.The recurrent architecture oftumourinitiation,progression and drug sensitivity.Nat Rev Cancer.2017;17:116-130.doi:110.1038 / nrc.2016.1124.Epub 2016Dec 1015.27.Trusheim MR,Berndt ER.Theclinical benefits,ethics,and economics of stratified medicine and companiondiagnostics.Drug Discov Today.2015;20:1439-1450.doi:1410.1016 / j.drudis.2015.1410.1017.Epub 2015Nov 1433. 28.Modlin I,Drozdov I,Alaimo D,et al.Amultianalyte PCRblood testoutperforms single analyte ELISAs forneuroendocrine tumor detectionEndocrRelat Cancer.2014;21:615-628. 29.Li XJ,Hayward C,Fong PY,et al.A blood-based proteomic classifierfor the molecular characterization of pulmonary nodules.Sci Transl Med.2013;5:207ra142.doi:210.1126 / scitranslmed.3007013. 30.Kaijser J,Sayasneh A,Van Hoorde K,et al.Presurgical diagnosis ofadnexal tumours using mathematical models and scoring systems:a systematicreview and meta-analysis.Hum Reprod Update.2014;20:449-462.doi:410.1093 / humupd / dmt1059.Epub 2013Dec 1099. 31.Risch HA,Lu L,Streicher SA,et al.Aspirin Use and Reduced Risk ofPancreatic Cancer.Cancer Epidemiol Biomarkers Prev.2017;26:68-74.doi:10.1158 / 1055-9965.EPI-1116-0508.Epub2016Dec 1120. 32.Ballman KV.Biomarker:Predictive or Prognostic?J Clin Oncol.2015;33:3968-3971.doi:3910.1200 / JCO.2015.3963.3651.Epub 2015Sep 3921. 33. Pritzker KP. Predictive and prognostic cancer biomarkers revised. Expert Rev Mol Diagn. 2015;15:971-974.doi:910.1586 / 14737159.14732015.11063421.Epub 14732015Jul 14737151.

[0145] Equivalent Although the present invention has been described in conjunction with the above specific embodiments, many alternatives, modifications and other variations will be apparent to those skilled in the art. All such alternatives, modifications and variations are intended to fall within the spirit and scope of the present invention.

Claims

1. Use of multiple reagents for specifically detecting the expression of 12 biomarkers in the preparation of a kit for providing peptide receptor radiotherapy (PRRT) treatment recommendations for a subject with a neuroendocrine tumor (NET) by the following method, the method comprising: determining the expression levels of at least 12 biomarkers from the test sample by contacting the test sample from the subject with a plurality of reagents that specifically detect the expression of at least 12 biomarkers, wherein the 12 biomarkers comprise ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3, TECPR2, and ALG9; The expression level of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3, and TECPR2 was normalized to the expression level of ALG9 to obtain the normalized expression level of each of ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3, and TECPR2; Scores were determined based on normalized expression levels; Determine the histological grade of NET; Based on the score and the histological grade of the NET, it is predicted whether a subject with NET will respond to the PRRT.

2. The use of claim 1, wherein when the NET is a G1 or G2 NET, the NET is designated as a low grade, or wherein when the NET is a G3 NET, the NET is designated as a high grade.

3. The use of claim 1, wherein at least one of the biomarkers is RNA, cDNA or protein.

4. The use according to any one of claims 1 to 3, wherein when at least one of the biomarkers is RNA, the RNA is reverse transcribed to produce cDNA, and the expression level of the produced cDNA is detected.

5. The use of claim 3, wherein the expression level of the biomarker is detected by forming a complex between the biomarker and a labeled probe or primer.

6. The use of claim 3, wherein when at least one of the biomarkers is a protein, the protein is detected by forming a complex between the protein and a labeled antibody.

7. The use of claim 3, wherein when at least one of the biomarkers is RNA or cDNA, the RNA or cDNA is detected by forming a complex between the RNA or cDNA and a labeled nucleic acid probe or primer.

8. The use of claim 7, wherein the complex between the RNA or cDNA and the labeled nucleic acid probe or primer is a hybridization complex.

9. The use according to any one of claims 1 to 3, wherein the test sample is blood, serum, plasma or neoplastic tissue.

10. The use according to claim 9, wherein the test sample is blood.

11. The use according to any one of claims 1 to 3, wherein the PRRT is based on 177 Lu's PRRT.

12. The method of claim 11, wherein the method is based on 177 Lu's PRRT is 177 Lu-DOTA-Tyr 3 -Thr8 -Octreotide.

Citation Information

Patent Citations

  • Anodes for electrochemical purposes

    EP0002017A1

  • Communication device, available band calculation system, available band calculation method, and program

    US20180062964A1